Is the Prescription of Antidepressants for Bipolar Depression Justified from the Point of View of Evidence-Based Medicine?

Background: prescribing antidepressants in the treatment of bipolar depression remains highly controversial due to the inconsistence between routine clinical practice and the results of controlled trials. Purpose: to assess the validity of antidepressants use in bipolar depression from the point of view of evidence-based medicine. Material: database search (Scopus and MEDLINE) followed by analysis of studies concerning the efficacy and safety of antidepressants in bipolar depression treatment. Сonclusion: the search found 23 studies. There was a high degree of inconsistency in the results, apparently related to the methodology. Only two studies compared the effectiveness of antidepressants in monotherapy with placebo, with no differences found in the study with 740 participants and in the study with 70 participants with type 2 bipolar disorder antidepressants were found to be more effective than placebo. Nevertheless, both studies had significant methodological issues. In 6 studies comparing the effectiveness of the combination of antidepressants with mood stabilizers against the combination of mood stabilizers with placebo, only the effectiveness of fluoxetine in combination with olanzapine was revealed, other antidepressants were ineffective. At the same time, studies where antidepressants were compared with each other in combination with mood stabilizers revealed a significant clinical response to therapy. Analysis of routine clinical practice studies has shown that antidepressants are prescribed very often, for about 50% of patients with bipolar depression. International guidelines for therapy differ quite widely on the use of antidepressants in bipolar depression, but in principle allow their use. Thus, despite the contradictory literature data, the use of antidepressants in bipolar depression is justified from the point of view of evidence-based medicine for certain groups of patients with taking into account risk factors.

1. Ivanov SV. Valdoxan in therapy of bipolar depression: results from Russian multicenter naturalistic study “Chronos”. V.M. Bekhterev review of psychiatry and medical psychology. 2011;(2):26–29. (In Russ.). https://elibrary.ru/item.asp?id=17701061

2. Sorokin SA. Clinical and dynamic features of endogenous affective disorders occurring with apathetic depressions. Psychiatry. 2018;1(77):26–31. DOI:10.30629/2618-6667-2018-77-26-31 (In Russ.).

3. Panteleeva GP, Oleichik IV, Abramova LI, Yumatova PE. Treatment of endogenous depression with venflaxine: clinical action, tolerability and personalized treatment options. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova. 2015;115(1–2):43–51. DOI:10.17116/jnevro20151152243-51 (In Russ.).

4. McIntyre RS, Cha DS, Kim RD, Mansur RB. A review of FDA-approved treatment options in bipolar depression. CNS Spectr. 2013;18(1):4–20; quiz 21. DOI:10.1017/S1092852913000746

5. Gosudarstvennyj reestr lekarstvennyh sredstv. http://grls.rosminzdrav.ru/Default.aspx (In Russ.).

6. Morsel AM, Morrens M, Sabbe B. An overview of pharmacotherapy for bipolar I disorder. Expert Opinion on Pharmacotherapy. 2018;19(3):203–222. DOI:10.1080/14656566.2018.1426746

7. Post RM, Altshuler LL, Leverich GS, Frye MA, Nolen WA, Kupka RW, Suppes T, McElroy S, Keck PE, Denicoff KD., Grunze H, Walden J, Kitchen CMR, Mintz J Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br. J. Psychiatry. 2006;189:124–131. DOI:10.1192/bjp.bp.105.013045

8. McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J. Clin. Psychiatry. 2010;71(2):163–174. DOI:10.4088/JCP.08m04942gre

9. Agosti V, Stewart JW. Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression. Int. Clin. Psychopharmacol. 2007;22(5):309–311. DOI:10.1097/YIC.0b013e3280c28410

10. Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, Oakes R, Pitts CD Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am. J. Psychiatry. 2001;158(6):906–912. DOI:10.1176/appi.ajp.158.6.906

11. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry. 2003;60(11):1079–1088. DOI:10.1001/archpsyc.60.11.1079

12. Sachs GS, Nierenberg AA, Calabrese JR, Maangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, Ketter TA, Patel J, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N. Engl. J. Med. 2007;356(17):1711–1722. DOI:10.1056/NEJMoa064135

13. Yatham LN, Vieta E, Goodwin GM, Bourin M, de Bodinat C, Laredo J, Calabrese J, Agomelatine Study Group. Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial. Br. J. Psychiatry. 2016;208(1):78–86. DOI:10.1192/bjp.bp.114.147587

14. Ghaemi SN, Vohringer PA, Pakar A. Citalopram for acute and preventive efficacy in bipolar depressiom (CAPE–BD): double-blind randomized, placebo-controlled trial (ClinicalTrials.gov Identifier: NCT00562861). https://clinicaltrials.gov/ct2/show/results/NCT00562861?term=citalopram&cond=Bipolar+Depression&draw=2&rank=2 Published 2016

15. Detke HC, Delbello MP, Landry J, Usher RW. Olanzapine/fluoxetine combination in children and adolescents with bipolar i depression: A randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2015;54(3):217–224. DOI:10.1016/Jjaac.2014.12.012

16. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am. J. Psychiatry. 1991;148(7):910–916. DOI:10.1176/ajp.148.7.910

17. Pilhatsch M, Wolf R, Winter C, Lewitzka U, Bauer M. Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: A reanalysis of a randomized, double-blind study. Journal of Affective Disorders. 2010;126(3):453–457. DOI:10.1016/Jjad.2010.04.025

18. Frye MA, Helleman G, McElroy SL, Altshuler LL, Black DO., Keck Jr PE, Nolen WA, Kupka R, Leverich GS, Grunze H, Mintz J, Post RM, Suppes T. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. American Journal of Psychiatry. 2009;166(2):164–172. DOI:10.1176/appi.ajp.2008.08030322

19. Bocchetta A, Bernardi F, Burrai C, Pedditzi M, Del Zompo M A double-blind study of L-sulpiride versus amitriptyline in lithium-maintained bipolar depressives. Acta Psychiatr. Scand. 1993;88(6):434–439. DOI:10.1111/J1600-0447.1993.tb03487.x

20. Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J. Clin. Psychiatry. 2004;65(12):1715–1719. DOI:10.4088/jcp.v65n1218

21. Silverstone T. Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatr. Scand. 2001;104(2):104–109. DOI:10.1034/J1600-0447.2001.00240.x

22. Mendlewicz J, Youdim MB. Antidepressant potentiation of 5-hydroxytryptophan by L-deprenil in affective illness. J. Affect. Disord. 1980;2(2):137–146. DOI:10.1016/0165-0327(80)90013-0

23. Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int. Clin. Psychopharmacol. 1989;4(4):313–322. DOI:10.1097/00004850-198910000-00006

24. Amsterdam JD, Shults J. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. J. Clin. Psychopharmacol. 2008;28(2):171–181. DOI:10.1097/JCP.0b013e318166c4e6

25. Amsterdam JD, Shults J. Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode. J. Clin. Psychopharmacol. 2010;30(3):306–311. DOI:10.1097/JCP.0b013e3181da5300

26. van der Loos MLM, Mulder P, Hartong EGTM, Blom MBJ, Vergouwen AC, van Noorden MS, Timmermans MA, Vieta E., Nolen WA, LamLit Study GrouP Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatr. Scand. 2010;122(3):246–254. DOI:10.1111/J1600-0447.2009.01537.x

27. Amsterdam JD, Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: A randomized, double-blind, placebo-substitution study. American Journal of Psychiatry. 2010;167(7):792–800. DOI:10.1176/appi.ajp.2009.09020284

28. Kauer-Sant’Anna M, Frey BN, Fijtman A, Loredo-Souza AC, Dargél AA, Pfaffenseller B, Wollenhaupt-Aguiar B, Gazalle FK, Colpo GD, Passos IC, Bücker J, Walz JC, Jansen K, Mendes Ceresér KM, Bürke Bridi KP, dos Santos Sória L, Kunz M, Pinho M, Kapczinski NS, Goi PD, Magalhães PVS, Reckziegel R, Burque RK, de Azevedo Cardoso T, Kapczinski F. Adjunctive tianeptine treatment for bipolar disorder: A 24-week randomized, placebo-controlled, maintenance trial. Journal of Psychopharmacology. 2019;33(4):502–510. DOI:10.1177/0269881119826602

29. Altshuler LL, Post RM, Hellemann G, Leverich GS, Nolen WA, Frye MA, Keck Jr PE, Kupka RW, Grunze H, McElroy SL, Sugar CA, Suppes T. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: A blinded, randomized study. Journal of Clinical Psychiatry. 2009;70(4):450–457. DOI:10.4088/JCP.08m04191

30. McGirr A, V ö hringer PA, Ghaemi SN, Lam RW, Yatham LN. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry. 2016;3(12):1138–1146. DOI:10.1016/S2215-0366(16)30264-4

31. Ketter TA. Acute and maintenance treatments for bipolar depression. J. Clin. Psychiatry. 2014;75(4):e10. DOI:10.4088/JCP.13010tx2c

32. El–Mallakh RS, V ö hringer PA, Ostacher MM, Baldassano CF, Holtzman NS, Whitham EA, Thommi SB, Goodwin FK, Ghaemi SN. Antidepressants worsen rapid-cycling course in bipolar depression: A STEP-BD randomized clinical trial. Journal of Affective Disorders. 2015;184:318–321. DOI:10.1016/Jjad.2015.04.054

33. Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, Coghill DR, Fazel S, Geddes JR, Grunze H, Holmes EA, Howes O., Hudson S, Hunt N, Jones I, Macmillan IC, McAllister–Williams H, Miklowitz DR, Morriss R, Munaf ò M, Paton C, Saharkian BJ, Saunders K, Sinclair J, Taylor D, Vieta E, Young AH. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J. Psychopharmacol (Oxford). 2016;30(6):495–553. DOI:10.1177/0269881116636545

34. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, Alda M, MacQueen G, Milev RV, Ravindran A, O’Donovan C, McIntosh D, Lam RW, Vazquez G, Kapczinski F, McIntyre RS, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese JR, Vieta E, Malhi G, Post RM, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170. DOI:10.1111/bdi.12609

35. Fountoulakis KN, Grunze H, Vieta E, Young A, Yatham L, Blier P, Kasper S, Moeller HJ The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines. Int. J. Neuropsychopharmacol. 2017;20(2):180–195. DOI:10.1093/ijnp/pyw109

36. National Collaborating Centre for Mental Health (UK). Bipolar Disorder: The NICE Guideline on the Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care. London: The British Psychological Society and The Royal College of Psychiatrists; 2014. http://www.ncbi.nlm.nih.gov/books/NBK498655/. Accessed December 23, 2019

37. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller H-J, Kasper S, WFSBP Task Force On Treatment Guidelines For Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J. Biol. Psychiatry. 2010;11(2):81–109. DOI:10.3109/15622970903555881

38. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am. J. Psychiatry. 2002;159(4):1–50.

39. Lim PZ, Tunis SL, Edell WS, Jensik SE, Tohen M. Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines. Bipolar Disorders. 2001;3(4):165–173. DOI:10.1034/J1399-5618.2001.30401.x

40. Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, Hennen J Patterns of Psychotropic Drug Prescription for U.S. Patients With Diagnoses of Bipolar Disorders. PS. 2007;58(1):85–91. DOI:10.1176/ps.2007.58.1.85

41. Freeland KN, Cogdill BR, Ross CA, Sullivan CO, Drayton SJ, VandenBerg AM, Short EB, Garrison KL. Adherence to evidence-based treatment guidelines for bipolar depression in an inpatient setting. Am. J. Health Syst. Pharm. 2015;72(23–3):S156–161. DOI:10.2146/sp150023

42. Rej S, Herrmann N, Shulman K, Fischer HD, Fung K, Gruneir A. Current psychotropic medication prescribing patterns in late-life bipolar disorder. International Journal of Geriatric Psychiatry. 2017;32(12):1459–1465. DOI:10.1002/gps.4635

43. Wang Z , Gao K, Hong W, Xing M, Wu Z , Chen J, Zhang C, Yuan C, Huang J, Peng D, Wang Y., Lu W, Yi Z , Yu X, Zhao J, Fang Y. Guidelines Disconcordance in Acute Bipolar Depression: Data from the National Bipolar Mania Pathway Survey (BIPAS) in Mainland China. PLOS ONE 2014;9(4):96096. DOI:10.1371/journal.pone.0096096

44. Bjørklund L, Horsdal HT, Mors O, Østergaard SD, Gasse C Trends in the psychopharmacological treatment of bipolar disorder: a nationwide register-based study. Acta Neuropsychiatrica. 2016;28(2):75–84. DOI:10.1017/neu.2015.52

45. Baek JH, Ha K, Yatham LN, Chang JS, Ha TH, Jeon HJ, Hong KS, Chang SM, Ahn YM, Cho HS, Moon E, Cha B, Choi JE, Joo YH, Joo EJ, Lee SY, Park Y. Pattern of Pharmacotherapy by Episode Types for Patients With Bipolar Disorders and Its Concordance With Treatment Guidelines. Journal of Clinical Psychopharmacology. 2014;34(5):577. DOI:10.1097/JCP.0000000000000175

46. Karanti A, Kardell M, Lundberg U, Landén M. Changes in mood stabilizer prescription patterns in bipolar disorder. Journal of Affective Disorders. 2016;195:50–56. DOI:10.1016/Jjad.2016.01.043

47. Goldberg JF, Freeman MP, Balon R, Citrome L, Thase ME, Kane JM, Fava M. The American Society of Clinical Psychopharmacology Survey of Psychopharmacologists’ Practice Patterns for the Treatment of Mood Disorders. Depression and Anxiety. 2015;32(8):605–613. DOI:10.1002/da.22378

48. Viktorin A, Lichtenstein P, Thase ME, Larsson H, Lundholm C, Magnusson PKE, Landén M. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am. J. Psychiatry. 2014;171(10):1067–1073. DOI:10.1176/appi.ajp.2014.13111501